The obesity management market is predicted to garner considerable revenue in the future due to steep rise in the prevalence of obesity over the past two decades. The statistics of prevalence of obesity and associated lifestyle diseases are alarming. According to records, in 2014, worldwide, more than half a billion people were registered obese and almost 2 billion adults were registered to be overweight. In the U.S., nearly 40% of the population was registered to be obese and nearly 70% of the population overweight in the same year.
Furthermore, every year, nearly 3 million people deaths are related to overweight or obesity. And, obesity accounts for almost half of Type 2 diabetes cases world over.
Due to such alarming statistics, weight loss and obesity management is important for the control of chronic diseases such as high cholesterol, diabetes, and heart disease for a healthy life.
The obesity management market is fairly consolidated with a few large players in the fray. R&D for product innovation and for development of existing products is what large players in the obesity management market are engaged in.
Prominent companies operating in the obesity management market are Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Apollo Endosurgery, Merck Sharp & Dohme Corp. GlaxoSmithKline plc, Herbalife Ltd., and Ethicon Inc.
High consumption of calorie-loaded foods and sedentary lifestyle are some key causes of obesity world over. High consumption of processed foods for long periods of time that are loaded with calories, combined with physical inactivity results in fat accumulation in the body. Over a period of time, consumption of such foods large quantities leads to overweight and obesity.
Furthermore, habits of overeating food habits, frequency of eating, and a diet in simple carbohydrates are some other causes of obesity.
In developed countries, growing geriatric population, mainly because of improved healthcare leading to increase in life expectancy, is giving thrust to obesity management market. This is because geriatric people are more prone to accumulation of noticeable body fat with simultaneous loss of muscle mass and functioning capability. This makes the geriatric population key segment of the obesity management market short term as well as long term.
Besides this, genetics and side-effects of medication are related to obesity that needs to be treated with the help of obesity management programs. This fuels the obesity management market.
However, despite enormous benefits, some studies demonstrate adverse side effects of obesity management drugs if taken in the long term. Besides this, some studies demonstrate heart disease, sleep apnea, depression, and stroke to be linked with obesity drugs. Such safety concerns that have made patients wary of potential side-effects of obesity drugs is slowing the growth of obesity management market to some extent.
North America is predicted to hold substantial revenue in the obesity management market in the forthcoming years. Factors such as substantial awareness in the population, presence of major drug manufacturers, and increasing prevalence of obesity account for high growth of obesity management market in the region. The bupropion and naltrexone is the leading segment in the North America obesity management market, and is expected to maintain its lead making it highly attractive to stakeholders.
Europe accounts for substantial revenue to the obesity management market. High consumption of processed meats and high prevalence of lifestyle diseases are some key causes of obesity in the region. Availability of health programs to manage obesity and government led health centers for obesity management augurs well for growth of obesity management market in the region.
However, Asia Pacific is emerging as a key region in the obesity management market. Excessive rise in incidence of obesity in developing countries of the region due to changing lifestyle has led to emergence of obesity management programs. This fuels the obesity management market in the region.